← Who reports today · Health Care
Eli Lilly (LLY) earnings date & Q3 2026 results
Net income
$6,451M
up 15.5% y/y
Revenue
$24,397M
up 38.6% y/y
Operating income
$8,608M
up 16.9% y/y
Next report
~ Feb 3
not announced yet
The quarter in brief
Revenue rose 39% to $24.4 billion, and operating income grew 17% to $8,608 million. Diluted EPS rose 16% to $7.22 from $6.21.
Key growth driver: Revenue growth of +39% y/y — the report gives no segment split, so the driver is the whole business. · by the Q3 2026 report
- Revenue +38.6% — a 53% increase in volume, partially offset by a 15% decrease in realized prices
Source
«In Q3 2026, worldwide revenue was $24.4 billion, an increase of 39% compared with Q3 2025, driven by a 53% increase in volume, partially offset by a 15% decrease in realized prices.»
press release, 8-K
All figures in $M.
| Line item | Amount and change |
|---|---|
| Revenue | $24,397 · +38.6% |
| Cost of sales | $3,933 · +30.8% |
| Research and development | $4,247 · +22.5% |
| Marketing, selling, and administrative | $3,125 · +14.0% |
| Acquired IPR&D | $4,181 · +537% |
| Asset impairment, restructuring and other special charges | $303 · −17.0% |
| Operating income | $8,608 · +16.9% · 35.3% margin |
| Net interest income (expense) | $316 · +177% |
| Net other income (expense) | $114 · vs a $18 loss |
| Income before income taxes | $8,406 · +16.2% |
| Income tax expense | $1,955 · +18.5% · 23.3% effective rate |
| Net income | $6,451 · +15.5% · $7.22/sh · 26.4% margin |
Verdict: Revenue rose 39% to $24.4 billion, and operating income grew 17% to $8,608 million. Diluted EPS rose 16% to $7.22 from $6.21.
Full-year 2026 revenue guidance was raised to $91 to $92 billion from $85 to $87 billion. Non-GAAP EPS guidance was cut to $35.00 to $36.00 from $35.50 to $36.50. The dividend paid per share was $1.73 in Q3 2026, up 15% from $1.50.
Source and notation
Source: Eli Lilly and Company press release, 8-K EX-99.1 of 10/29/2026 (SEC EDGAR).
Open as an image: Eli Lilly (LLY), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “Eli Lilly (LLY) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/lly. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/lly"><img src="https://whoreportstoday.com/t/lly/img/eli-lilly-and-company-lly-earnings-sankey.png" alt="Eli Lilly (LLY) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/lly">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/lly/img/eli-lilly-and-company-lly-earnings-sankey.png
<a href="https://whoreportstoday.com/t/lly">Eli Lilly (LLY) Q3 2026 earnings chart (Who Reports Today)</a>
The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Volume rose 53% while realized prices fell 15%, and Q3 revenue included about $900 million of benefits, including $410 million of Jardiance milestones.
- Acquired IPR&D charges were $4,181 million vs $656 million, equal to $4.57 vs $0.71 of EPS, mainly from the AtaiBeckley and Curevo acquisitions.
- Net interest expense increased to $316 million from $114 million, partly offset by $114 million of net other income vs $18 million of expense.
- The effective tax rate rose to 23.3% from 22.8%.
- Diluted shares decreased to 893.4 million from 898.8 million.
What distorts the picture in this report and what to watch beyond the headlines.
Who runs the company now
- David RicksChair, President, and Chief Executive Officer [1]
- Lucas MontarceExecutive Vice President and Chief Financial Officer [2]
As of 11/18/2026, per the company’s SEC filings: signatures on the latest report and leadership-change filings.
Positions and previous jobs: the company’s SEC filings. Spotted an error, or is this you and you’d like it corrected or removed? Contact us
Where they worked before
- Eli Lillysince 2017
- Chair, President, and Chief Executive Officersince 2017
- Senior Vice President and President, Lilly Bio-Medicines
Source: SEC EDGAR: 10-K annual report, 2026-02-12 · as of 10/21/2026
- Eli Lillysince 2024
- Executive Vice President and Chief Financial Officersince 2024
- President and General Manager, Spain, Portugal, and Greece hub2024
- Group Vice President, Controller and Chief Financial Officer, Lilly Research Laboratories
Source: SEC EDGAR: 10-K annual report, 2026-02-12 · as of 10/21/2026
How this is compiled
Who runs the company now comes from primary sources only: for US and Canadian companies, the CEO and CFO signatures on the latest SEC report, and a separate board chair from the proxy materials; for Russian and Kazakh issuers, the company website and its disclosures. We recheck weekly; if a name can’t be confirmed, or a leadership-change filing came out after the report, we don’t show it until it’s reviewed. Previous jobs are only what the company itself disclosed about its current leaders (the past five years of business experience in the annual report and proxy materials): employer, position and years, restated as facts, with no age, education or other personal details. If the company doesn’t disclose it, we don’t look elsewhere. Anything more than 400 days past its last check is hidden. These are public business facts from disclosures, shown to tell investors who runs the company (our legitimate interest); if this is you and you object, contact us via the link above and we’ll remove it.
Sources · 2
- SEC EDGAR: 10-Q 2026-10-29 · SEC EDGAR · 11/18/2026
- SEC EDGAR: 10-Q 2026-10-29 · SEC EDGAR · 11/18/2026
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 36 countries. · Text: Wikipedia, CC BY-SA 4.0, abridged
Its products are marketed in approximately 90 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named. Market share (US pharma & biotech): ≈11% by TTM revenue.
Heads-up
- profit is growing slower than revenue: +16% vs +39% y/y in Q3 2026
Net income +16% y/y against revenue +39% y/y. In the report's figures: costs grew faster than revenue: acquired ipr&d +537% y/y, net interest income (expense) +177% y/y. Based on the Q3 2026 report.
The company's report ↗Company reports
Revenue by product
Quarter · Sep 30, 2026
| Product | $ millions | Y/Y |
|---|---|---|
| Net product revenue | 22,650 | +38.7% |
| Collaboration and other revenue | 1,747 | +37.6% |
Fiscal year · Dec 31, 2025
| Product | $ millions | Y/Y |
|---|---|---|
| Net product revenue | 60,958 | +49.6% |
| Collaboration and other revenue | 4,221 | -1.7% |
How we calculate
Year-over-year change uses the comparable prior-year period. When the fourth quarter is calculated from the year and nine months, both filings are linked.
Company guidance
| Period | Company guidance | A year ago | Implied growth |
|---|---|---|---|
| FY2026 | revenue $91–92B | revenue $65.2BEPS (GAAP) $22.95 | revenue +40…41% |
Same quarter a year ago (ended December 31, 2025): revenue $19.3B, EPS (GAAP) $7.39
How we calculate
Implied growth compares the low and high ends of the company's range with the same period a year ago (midpoint: +40%).
Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.
Guidance comes from the company's earnings release (Form 8-K filed Oct 29, 2026); every figure is checked against the release text.
LLY earnings history: past report dates
| Oct 29, 2026 Thu | 7:03 ambefore market open | Sep 30, 2026 | $24.4B+39% y/y | $7.22+16% y/y |
| Aug 5, 2026 Wed | 7:05 ambefore market open | Jun 30, 2026 | $23.0B+48% y/y | $7.94+26% y/y |
| Apr 30, 2026 Thu | 7:03 ambefore market open | Mar 31, 2026 | $19.8B+56% y/y | $8.26+170% y/y |
| Feb 4, 2026 Wed | 7:05 ambefore market open | Dec 31, 2025 | ≈$19.3B+43% y/y | ≈$7.39+51% y/y |
| Oct 30, 2025 Thu | 7:03 ambefore market open | Sep 30, 2025 | $17.6B+54% y/y | $6.21+480% y/y |
| Aug 7, 2025 Thu | 7:05 ambefore market open | Jun 30, 2025 | $15.6B+38% y/y | $6.29+92% y/y |
| May 1, 2025 Thu | 7:03 ambefore market open | Mar 31, 2025 | $12.7B+45% y/y | $3.06+23% y/y |
| Feb 6, 2025 Thu | 7:05 ambefore market open | Dec 31, 2024 | ≈$13.5B+45% y/y | ≈$4.88+102% y/y |
| Oct 30, 2024 Wed | 7:05 ambefore market open | Sep 30, 2024 | $11.4B+20% y/y | $1.07 |
| Aug 8, 2024 Thu | 7:04 ambefore market open | Jun 30, 2024 | $11.3B+36% y/y | $3.28+68% y/y |
| Apr 30, 2024 Tue | 7:04 ambefore market open | Mar 31, 2024 | $8.8B+26% y/y | $2.48+66% y/y |
| Feb 6, 2024 Tue | 7:04 ambefore market open | Dec 31, 2023 | ≈$9.4B+28% y/y | ≈$2.42+13% y/y |
| Nov 2, 2023 Thu | 7:02 ambefore market open | Sep 30, 2023 | $9.5B+37% y/y | −$0.06 |
| Aug 8, 2023 Tue | 7:01 ambefore market open | Jun 30, 2023 | $8.3B+28% y/y | $1.95+86% y/y |
| Apr 27, 2023 Thu | 7:02 ambefore market open | Mar 31, 2023 | $7.0B−11% y/y | $1.49−29% y/y |
| Feb 2, 2023 Thu | 7:13 ambefore market open | Dec 31, 2022 | ≈$7.3B−9% y/y | ≈$2.14+13% y/y |
| Nov 1, 2022 Tue | 7:03 ambefore market open | Sep 30, 2022 | $6.9B+2% y/y | $1.61+32% y/y |
| Aug 4, 2022 Thu | 7:05 ambefore market open | Jun 30, 2022 | $6.5B−4% y/y | $1.05−31% y/y |
| Apr 14, 2022 Thu | 4:57 pmafter market close | Mar 31, 2022 | $7.8B+15% y/y | $2.10+41% y/y |
| Feb 3, 2022 Thu | 7:08 ambefore market open | Dec 31, 2021 | ≈$8.0B+8% y/y | ≈$1.89−19% y/y |
| Oct 26, 2021 Tue | 7:06 ambefore market open | Sep 30, 2021 | $6.8B+18% y/y | $1.22−8% y/y |
| Aug 3, 2021 Tue | 7:37 ambefore market open | Jun 30, 2021 | $6.7B+23% y/y | $1.53−1% y/y |
| Apr 27, 2021 Tue | 6:48 ambefore market open | Mar 31, 2021 | $6.8B+16% y/y | $1.49−7% y/y |
| Jan 29, 2021 Fri | 6:32 ambefore market open | Dec 31, 2020 | ≈$7.4B+22% y/y | ≈$2.32+41% y/y |
| Oct 27, 2020 Tue | 7:50 ambefore market open | Sep 30, 2020 | $5.7B+5% y/y | $1.33−3% y/y |
| Jul 30, 2020 Thu | 7:03 ambefore market open | Jun 30, 2020 | $5.5B−2% y/y | $1.55+8% y/y |
| Apr 23, 2020 Thu | 8:02 ambefore market open | Mar 31, 2020 | $5.9B+15% y/y | $1.60−63% y/y |
| Jan 30, 2020 Thu | 6:29 ambefore market open | Dec 31, 2019 | $6.1B+8% y/y | $1.64+49% y/y |
| Oct 23, 2019 Wed | 7:28 ambefore market open | Sep 30, 2019 | $5.5B+3% y/y | $1.37+22% y/y |
| Jul 30, 2019 Tue | 11:27 amduring market hours | Jun 30, 2019 | $5.6B+1% y/y | $1.44 |
| Apr 30, 2019 Tue | 1:31 pmduring market hours | Mar 31, 2019 | $5.1B+3% y/y | $4.31+272% y/y |
| Feb 6, 2019 Wed | 9:48 amduring market hours | Dec 31, 2018 | $5.6B−8% y/y | $1.10 |
| Nov 6, 2018 Tue | 7:03 ambefore market open | Sep 30, 2018 | $5.3B−6% y/y | $1.12+111% y/y |
| Jul 24, 2018 Tue | 6:45 ambefore market open | Jun 30, 2018 | $5.6B−4% y/y | −$0.25 |
| Apr 24, 2018 Tue | 6:44 ambefore market open | Mar 31, 2018 | $5.0B−5% y/y | $1.16 |
| Jan 31, 2018 Wed | 8:32 ambefore market open | Dec 31, 2017 | $6.2B+7% y/y | −$1.58 |
| Oct 24, 2017 Tue | 6:30 ambefore market open | Sep 30, 2017 | $5.7B+9% y/y | $0.53−27% y/y |
| Jul 25, 2017 Tue | 6:36 ambefore market open | Jun 30, 2017 | $5.8B+8% y/y | $0.95+34% y/y |
| Apr 25, 2017 Tue | 6:28 ambefore market open | Mar 31, 2017 | $5.2B+7% y/y | −$0.10 |
| Jan 31, 2017 Tue | 8:54 ambefore market open | Dec 31, 2016 | $5.8B+7% y/y | $0.73+62% y/y |
| Oct 25, 2016 Tue | 6:28 ambefore market open | Sep 30, 2016 | $5.2B+5% y/y | $0.73−3% y/y |
| Jul 26, 2016 Tue | 6:25 ambefore market open | Jun 30, 2016 | $5.4B+9% y/y | $0.71+27% y/y |
| Oct 22, 2015 Thu | 6:25 ambefore market open | Sep 30, 2015 | $5.0B+2% y/y | $0.75+60% y/y |
| Jul 23, 2015 Thu | 8:26 ambefore market open | Jun 30, 2015 | $5.0B+1% y/y | $0.56−18% y/y |
| Apr 23, 2015 Thu | 6:42 ambefore market open | Mar 31, 2015 | $4.6B−1% y/y | $0.50−26% y/y |
| Jan 30, 2015 Fri | 8:06 ambefore market open | Dec 31, 2014 | $5.1B−12% y/y | $0.40−40% y/y |
| Oct 23, 2014 Thu | 6:41 ambefore market open | Sep 30, 2014 | $4.9B−16% y/y | $0.47−58% y/y |
| Jul 24, 2014 Thu | 6:36 ambefore market open | Jun 30, 2014 | $4.9B−17% y/y | $0.68−39% y/y |
| Apr 24, 2014 Thu | 6:41 ambefore market open | Mar 31, 2014 | $4.7B−16% y/y | $0.68−52% y/y |
| Jan 7, 2014 Tue | 7:02 ambefore market open | Dec 31, 2013 | $5.8B−2% y/y | $0.67−9% y/y |
| Oct 23, 2013 Wed | 6:36 ambefore market open | Sep 30, 2013 | $5.8B+6% y/y | $1.11−6% y/y |
| Jul 24, 2013 Wed | 6:37 ambefore market open | Jun 30, 2013 | $5.9B+6% y/y | $1.11+34% y/y |
| Apr 24, 2013 Wed | 6:34 ambefore market open | Mar 31, 2013 | $5.6B+0% y/y | $1.42+56% y/y |
| Jan 29, 2013 Tue | 6:36 ambefore market open | Dec 31, 2012 | $6.0B−1% y/y | $0.74−4% y/y |
| Oct 24, 2012 Wed | 6:34 ambefore market open | Sep 30, 2012 | $5.4B−11% y/y | $1.18+6% y/y |
Show all 55 reports since 2012Show fewer
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Eli Lilly: 15-year financials
| 2025 | 65,179 | 20,640 | 8,972 | 5,384 |
| 2024 | 45,043 | 10,590 | 3,760 | 4,680 |
| 2023 | 34,124 | 5,240 | 792 | 4,069 |
| 2022 | 28,541 | 6,245 | 5,731 | 3,536 |
| 2021 | 28,318 | 5,582 | 6,056 | 3,087 |
| 2020 | 24,540 | 6,194 | 5,112 | 2,687 |
| 2019 | 22,320 | 8,318 | 3,803 | 2,410 |
| 2018 | 21,493 | 3,232 | 4,314 | 2,312 |
| 2017 | 19,974 | −204 | 4,539 | 2,192 |
| 2016 | 21,222 | 2,738 | 3,814 | 2,159 |
| 2015 | 19,959 | 2,408 | 1,898 | 2,127 |
| 2014 | 19,616 | 2,391 | 3,296 | 2,101 |
| 2013 | 23,113 | 4,685 | 4,723 | 2,121 |
| 2012 | 22,603 | 4,089 | 4,399 | 2,187 |
| 2011 | 24,287 | 4,348 | 6,563 | 2,180 |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.
How we calculate
Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. New annual filings are checked in the nightly SEC refresh. The filing history starts in 2011. Where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.
Eli Lilly: 15-year balance sheet
| Year | Assets | Equity | Debt | Cash | Current assets | Current liabilities |
|---|---|---|---|---|---|---|
| 20252025-12-31 | 112,476 | 26,535 | 42,503 | 7,268 | 55,629 | 35,228 |
| 2024 | 78,715 | 14,272 | 33,812 | 3,268 | 32,740 | 28,376 |
| 2023 | 64,006 | 10,772 | 25,294 | 2,819 | 25,727 | 27,293 |
| 2022 | 49,490 | 10,650 | 16,313 | 2,067 | 18,035 | 17,138 |
| 2021 | 48,806 | 8,979 | 16,741 | 3,819 | 18,452 | 15,053 |
| 2020 | 46,633 | 5,642 | 16,349 | 3,657 | 17,462 | 12,482 |
| 2019 | 39,286 | 2,607 | 15,133 | 2,338 | 13,710 | 11,775 |
| 2018 | 43,908 | 9,829 | 10,798 | 7,321 | 20,550 | 11,888 |
| 2017 | 44,981 | 11,592 | 16,344 | 6,536 | 19,202 | 14,536 |
| 2016 | 38,806 | 14,008 | 10,305 | 4,582 | 15,101 | 10,987 |
| 2015 | 35,569 | 14,571 | 7,979 | 3,666 | 12,574 | 8,230 |
| 2014 | 36,308 | 15,373 | 10,702 | 3,872 | 11,928 | 9,741 |
| 2013 | 35,249 | 17,631 | 6,226 | 3,830 | 13,105 | 8,917 |
| 2012 | 34,399 | 14,765 | 5,543 | 4,019 | 13,039 | 8,390 |
| 2011 | 33,660 | 13,542 | 8,504 | 5,923 | 14,248 | 8,931 |
$ millions, at fiscal year-end*.
* Sources
How we calculate
Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual figures use SEC XBRL. The nightly SEC check adds balance sheets from new annual filings. Earlier years use the screener’s filing history. Amounts use the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .
Cash flow, 1 year
| Year | CFO · Operating cash flow | CAPEX · Capital expenditure | FCF · Free cash flowcalculated | FCF margin, %calculated | Dividends paid | Share buybacks | FCF / net income, %calculated | CFI · Investing cash flow | CFF · Financing cash flow |
|---|---|---|---|---|---|---|---|---|---|
| 20252025-12-31 | 16,813 | — | — | — | — | 4,108 | — | −10,972 | −2,213 |
More detailsHide details
$ millions, per fiscal year; ratios in %. “—” — no verified data or calculation not applicable.
* Sources
How we calculate
CFO, CFI and CFF are net operating, investing and financing cash flows. CAPEX is a positive cash outflow for capital expenditure; its scope follows the issuer document line. FCF = CFO − CAPEX; lease repayments are not deducted separately. If no separately sourced numeric CAPEX amount is available, CAPEX and FCF calculations are omitted. FCF margin = FCF / same-year revenue × 100. FCF / net income = FCF / same-year income attributable to shareholders × 100; losses or zero income produce a dash. Revenue and income use this card’s indicators table; missing or mismatched periods produce no ratio. Dividends and common share buybacks are actual annual cash payments from the cash flow statement, shown as positive cash outflows; payments to noncontrolling interests and share-compensation withholding taxes are excluded. Zero requires document evidence. Buybacks appear only if at least one reviewed payment exists in the fifteen-year window. The window is fifteen years; years without a single value are omitted. All listed years stay open; CFI, CFF and buybacks for Russia and Kazakhstan appear under More details.
Snapshot reviewed: . Updated after annual filings and three checks against issuer documents. Unreviewed and interim periods are excluded from the annual series.
More: latest reported period
9 months ended 2026-09-30 · $M
| Line | This period | Year ago | Δ |
|---|---|---|---|
| Operating cash flowcash the business generated | 27,420 | 13,588 | +13,832 |
| · incl. D&A (non-cash add-back)depreciation & amortization | 1,588 | 1,411 | |
| · incl. stock-based comp (non-cash)share-based compensation | 562 | 490 | |
| Investing activities, netcapex, acquisitions, securities | −27,611 | −8,169 | −19,442 |
| Financing activities, netdebt, buybacks, dividends | −2,263 | 666 | −2,929 |
| · incl. buybacksrepurchases of common stock | −4,334 | −2,600 | −1,734 |
| · incl. dividends paid | −4,635 | −4,039 | −596 |
| FX effect on cash | 71 | 439 | −368 |
| Net change in cash | −2,383 | 6,524 | −8,907 |
Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.
Dividends
$6.23 per share · 2025 ↗
Dividend history
| Year | $ per share | Paid, $ millions |
|---|---|---|
| 2025 | 6.23 | 5,384 |
| 2024 | 5.4 | 4,680 |
| 2023 | 4.69 | 4,069 |
| 2022 | 4.07 | 3,535.8 |
| 2021 | 3.53 | 3,086.8 |
| 2020 | 3.07 | 2,687.1 |
| 2019 | 2.68 | 2,409.8 |
| 2018 | 2.33 | 2,311.8 |
| 2017 | 2.12 | 2,192.1 |
| 2016 | 2.05 | 2,158.5 |
| 2015 | — | 2,127.3 |
| 2014 | — | 2,101.2 |
| 2013 | — | 2,120.7 |
| 2012 | — | 2,187.4 |
| 2011 | 1.96 | 2,180.1 |
Per-share amounts are split-adjusted. Total payments come from the annual filings. SEC annual filings ↗
Shares outstanding and buybacks
943.36 million shares · Feb 9, 2026 ↗
4,108 million USD spent on buybacks · 2025 ↗
Share counts and buybacks by year
| Year | Million shares | Buybacks, $ millions |
|---|---|---|
| 2025Feb 9, 2026 | 943.36 | 4,108 |
| 2024Feb 14, 2025 | 948.17 | — |
| 2023Feb 16, 2024 | 950.16 | — |
| 2022Feb 17, 2023 | 950.3 | — |
| 2021Feb 18, 2022 | 952.35 | — |
| 2020Feb 12, 2021 | 958.43 | — |
| 2019Feb 13, 2020 | 956.38 | — |
| 2018Feb 13, 2019 | 1,035.42 | — |
| 2017Feb 14, 2018 | 1,095.6 | — |
| 2016Feb 13, 2017 | 1,103.35 | — |
| 2015Feb 12, 2016 | 1,106.09 | — |
| 2014Feb 13, 2015 | 1,111.1 | — |
| 2013Feb 14, 2014 | 1,119.71 | — |
| 2012Feb 15, 2013 | 1,134.41 | — |
| 2011Feb 15, 2012 | 1,160.41 | — |
Share counts are shown as of the date stated in each filing. Buybacks, new shares and splits can all change the count.
Industry comparison
| Metric | Company | Median |
|---|---|---|
| Net debt / EBITDA | 1.23× | 2.45× |
| Debt / Equity | 1.23× | 0.83× |
| Interest coverage | 40.00× | 3.09× |
| Current ratio | 1.39× | 2.35× |
| Gross margin | 83.7% | 61.5% |
| Operating margin | 40.8% | 18.3% |
| Net margin | 31.3% | 14.7% |
| ROE | 65.9% | 14.6% |
| ROA | 17.9% | 6.5% |
Sample and sources
US pharma & biotech · median from 46 companies. Company figures use the last four quarters and the balance sheet at Sep 30, 2026. Industry snapshot dated Sep 1, 2026, using SEC calendar-year 2025 data. Latest annual filing ↗ · SEC XBRL revenue ↗ · SEC XBRL assets ↗
Shareholders’ equity at Sep 30, 2026: $40.3B (27% of total assets). Compare with other S&P 500 companies →
Corporate governance
2/2good
- Feb 20262025 10-K: a single class of stock — LLY common; the legal proceedings section shows no shareholder disclosure suits or SEC investigations. sec.gov ↗
- Dec 2025Dividend per share rose from $3.07 (2020) to $6.23 (2025); diluted share count fell 1.5% over 5 years. data.sec.gov ↗
1 more fact and scoring
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
- Apr 2008In the shareholder class action In re Eli Lilly Securities Litigation (Zyprexa, 2007), the court ruled in the company's favor in April 2008. sec.gov ↗
Scoring: 2.0, no deductions: single class of stock, share count −1.5% over 5 years, dividend raised every year, buybacks; the 2007 Zyprexa class action ended with a ruling in the company's favor (2008); the 2012 SEC penalty was under the FCPA, not a deduction
- Share classes
- Single class — LLY common stock on the NYSE (cover of 2025 10-K).
- Dilution
- Diluted share count 2020→2025 −1.5% (XBRL); SBC 1.0% of revenue — no deduction.
- Disclosure
- Full 10-K/10-Q reporting.
- Dividends
- Dividend per share raised every year: $3.07 (2020) → $6.23 (2025); buybacks of $0.75–4.1B a year.
- Lawsuits & regulators
- The 2025 10-K shows no shareholder disclosure suits or SEC cases; the 2007 shareholder suit (Zyprexa) ended with a ruling in Lilly's favor in April 2008; the 2012 SEC matter ($29.4M) was under the FCPA and is not deducted under the methodology.
- Related parties
- The 2026 proxy discloses no material related-party transactions; Lilly Endowment is a large shareholder with no special rights (single class of stock).
How the score works · checked as of Oct 2026
Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap
Eli Lilly (LLY) earnings: FAQ
When is LLY's next earnings date?
We have not yet seen an announcement of the date from Eli Lilly (LLY). Based on last year's report on Feb 4, 2026, the next report is expected around Feb 3, 2027.
What time does LLY report earnings?
Eli Lilly usually reports before market open: its latest results release was filed with the SEC at 7:03 am ET on Oct 29, 2026.
When did LLY last report earnings?
Eli Lilly reported Q3 2026 results on Oct 29, 2026.
What has Eli Lilly guided for FY2026?
Company guidance for FY2026: revenue $91–92B. A year ago (FY2025): revenue $65.2B, EPS (GAAP) $22.95. Implied growth: revenue +40…41%. Source: the company's earnings release (Form 8-K filed Oct 29, 2026).
Where can I find Eli Lilly's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to LLY's filings; this page breaks the latest report down in a Sankey chart.
What was LLY's net income in Q3 2026?
Eli Lilly reported net income of $6,451M for Q3 2026 (+15.5% year over year), under US GAAP.
Does Eli Lilly pay dividends?
Yes. In 2025, Eli Lilly paid $5,384M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.
How has Eli Lilly's revenue changed since 2011?
Per its 10-K filings, revenue grew 2.7x: $24,287M in 2011 and $65,179M in 2025. The latest year is the highest in the table. Year-by-year figures are in the table above.
New to earnings reports? Start with how to read an earnings report.
Get it every Monday: who reports this week
Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.
More reports: MCK · Q1 FY2027 · MDT · Q1 2027 · MRK · Q3 2026 · MRNA · Q2 2026 · MTD · Q3 2026 · PFE · Q3 2026 · PODD · Q3 2026 · REGN · Q3 2026 · RMD · Q1 FY2027 · RVTY · Q3 2026 · all reports